Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles

Journal of Vascular Research

Volumn 43, Issue 1, 2005, Pages 86-94

  Nakamura, Kazuya ^a   Ikomi, Fumitaka ^a   Ohhashi, Toshio ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebral penetrating arteriole; Cilostazol; Milrinone; Phosphodiesterase 3 inhibitor; Vasodilative prostaglandins

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP PHOSPHODIESTERASE; IBERIOTOXIN; MILRINONE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BRAIN; BRAIN INFARCTION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; EVALUATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ARTERIOLES; ASPIRIN; CEREBROVASCULAR CIRCULATION; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLYBURIDE; HYPOGLYCEMIC AGENTS; MALE; MILRINONE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE; PHOSPHODIESTERASE INHIBITORS; PRESSURE; PROSTAGLANDINS; RABBITS; TETRAZOLES; VASODILATION; VASODILATOR AGENTS;

EID: 29244436796     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089723     Document Type: Article

References (25)

1. Kawamura K, Fujita S, Tani T, Kimura Y: Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency. Arzneimittelforschung 1985;35:1154-1156.
2. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-1149.
3. Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, Ito R, Ishida K, Matsumoto Y, Kimura Y: Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-268.
4. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y: Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 2002;16:417-427.
5. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, et al: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-157.
6. Kobayashi S, Yamaguchi S, Katsube T, Kitani M, Okada K, Tsunematsu T: Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. Arzneimittelforschung 1985;35:1193-1197.
7. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
8. Yashiro Y, Ohhashi T: Flow- and agonist-mediated nitric oxide- and prostaglandin-dependent dilation in spinal arteries. Am J Physiol 1997;273:H2217-H2223.
9. Mizuno R, Ono N, Ohhashi T: Involvement of ATP-sensitive K(+) channels in spontaneous activity of isolated lymph microvessels in rats. Am J Physiol 1999;277:H1453-H1456.
10. + channels. Circ Res 1995;76:1057-1062.
11. Ferro A, Coash M, Yamamoto T, Rob J, Ji Y, Queen L: Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Br J Pharmacol 2004;143:397-403.
12. Uchikawa T, Murakami T, Furukawa H: Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 1992;42:322-324.
13. Shintani S, Watanabe K, Kawamura K, Mori T, Tani T, et al: General pharmacological properties of cilostazol, a new antithrombotic drug. 2. Effect on the peripheral organs. Arzneimittelforschung 1985;35:1163-1172.
14. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J: The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004;24:1352-1358.
15. Wu SN, Liu SI, Huang MH: Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Endocrinology 2004;145:1175-1184.
16. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: bringing the concepts together. Trends Pharmacol Sci 2002;23:374-380.
17. Yashiro Y, Ohhashi T: Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. Jpn J Physiol 2002;52:471-477.
18. Birk S, Edvinsson L, Olesen J, Kruuse C: Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 2004;489:93-100.
19. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, Nakaya Y: Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-1715.
20. Winn HR, Rubio R, Berne RM: Brain adenosine production in the rat during 60 seconds of ischemia. Circ Res 1979;45:486-492.
21. O'Regan M: Adenosine and the regulation of cerebral blood flow. Neurol Res 2005;27:175-181.
22. Hein TW, Kuo L: cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res 1999;85:634-642.
23. 2+ channel activity via protein tyrosine phosphatase, not cAMP-dependent protein kinase. Mol Pharmacol 2003;64:640-649.
24. Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, Yoshitake M, Kambayashi J, Liu Y: Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497-504.
25. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-2302.